In Vitro Biopredictive Methods: A Workshop Summary Report.

Bioequivalence Biopredictive dissolution CQAs IVIVC IVIVR Modeling PBBM PBPK Permeability Precipitation Solubility

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
02 2021
Historique:
received: 19 08 2020
revised: 14 09 2020
accepted: 14 09 2020
pubmed: 22 9 2020
medline: 22 6 2021
entrez: 21 9 2020
Statut: ppublish

Résumé

This workshop report summarizes the proceedings of Day 1 of a three-day workshop on "Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls". Physiologically based biopharmaceutics models (PBBM) are tools which enable the drug product quality attributes to be linked to the in vivo performance. These tools rely on key quality inputs in order to provide reliable predictions. After introducing the objectives of the workshop and the expectations from the breakout sessions, Day 1 of the workshop focused on the best practices and challenges in measuring in vitro inputs needed for modeling, such as the drug solubility, the dissolution rate of the drug product, potential precipitation of the drug and drug permeability. This paper reports the podium presentations and summarizes breakout session discussions related to A) the best strategies for determining solubility, supersaturation and critical supersaturation; B) the best strategies for the development of biopredictive (clinically relevant) dissolution methods; C) the challenges associated with describing gastro-intestinal systems parameters such as mucus, liquid volume and motility; and D) the challenges with translating biopharmaceutical measures of drug permeability along the gastrointestinal tract to a meaningful model parameter.

Identifiants

pubmed: 32956678
pii: S0022-3549(20)30549-9
doi: 10.1016/j.xphs.2020.09.021
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-583

Subventions

Organisme : FDA HHS
ID : U01 FD005946
Pays : United States

Informations de copyright

Copyright © 2020 American Pharmacists Association®. All rights reserved.

Auteurs

Xavier J H Pepin (XJH)

New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK. Electronic address: Xavier.pepin@astrazeneca.com.

Jennifer Dressman (J)

Fraunhofer Institute for Molecular Biology and Applied Ecology and Goethe University, Frankfurt, Germany.

Neil Parrott (N)

Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.

Poonam Delvadia (P)

Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Amitava Mitra (A)

Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, Spring House, PA, USA.

Xinyuan Zhang (X)

Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Andrew Babiskin (A)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Vidula Kolhatkar (V)

Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Paul Seo (P)

Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Lynne S Taylor (LS)

Purdue University, College of Pharmacy, West Lafayette, IN, USA.

Erik Sjögren (E)

Pharmetheus, Uppsala, Sweden.

James M Butler (JM)

Biopharmaceutics, Drug Product Design & Dev, GlaxoSmithKline R&D, Ware, UK.

Edmund Kostewicz (E)

Institute of Pharmaceutical Technology, Goethe University, Frankfurt, Germany.

Christer Tannergren (C)

Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.

Mirko Koziolek (M)

University of Greifswald, Institute of Pharmacy, Greifswald, Germany; Current: NCE Formulation Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.

Filippos Kesisoglou (F)

Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, NJ, USA.

André Dallmann (A)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Yang Zhao (Y)

Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Sandra Suarez-Sharp (S)

Regulatory Affairs, Simulations Plus Inc., 42505 10th Street West, Lancaster, CA 93534, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

High-throughput Bronchus-on-a-Chip system for modeling the human bronchus.

Akina Mori, Marjolein Vermeer, Lenie J van den Broek et al.
1.00
Humans Bronchi Lab-On-A-Chip Devices Epithelial Cells Goblet Cells
1.00
Algorithms Computer Simulation Models, Biological Programming Languages Humans
Autophagy Humans Neoplasms Ubiquitination Animals

Classifications MeSH